CoChat

Graphical Tools for Network Meta-Analysis in STATA

Open access
Chaimani, Anna, Higgins, Julian P. T., Mavridis, Dimitris, Spyridonos, Panagiota, Salanti, Georgia · 2013 · PLoS ONE

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Network meta-analysis synthesizes direct and indirect evidence in a network of trials that compare multiple interventions and has the potential to rank the competing treatments according to the studied outcome. Despite its usefulness network meta-analysis is often criticized for its complexity and for being accessible only to researchers with strong statistical and computational skills. The evaluation of the underlying model assumptions, the statistical technicalities and presentation of the results in a concise and understandable way are all challenging aspects in the network meta-analysis methodology. In this paper we aim to make the methodology accessible to non-statisticians by presenting and explaining a series of graphical tools via worked examples. To this end, we provide a set of STATA routines that can be easily employed to present the evidence base, evaluate the assumptions, fit the network meta-analysis model and interpret its results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0076654

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Network plot of the acute mania network (efficacy outcome). Nodes are weighted according to the number of studies including the respective interventions. Edges are weighted according to the mean control group risk for comparisons between placebo and active treatment. Edges connecting two active treatments have been given minimal weight.
Figure 1 Network plot of the acute mania network (efficacy outcome). Nodes are weighted according to the number of studies including the respective interventions. Edges are weighted according to the mean control group risk for comparisons between placebo and active treatment. Edges connecting two active treatments have been given minimal weight.CC BY · PubMed Central
Figure 2 Plot of the acute mania network (efficacy outcome) using coloured edges according to adequacy of allocation concealment estimated as the level of bias in the majority of the trials and weighted according to the number of studies in each comparison.
Figure 2 Plot of the acute mania network (efficacy outcome) using coloured edges according to adequacy of allocation concealment estimated as the level of bias in the majority of the trials and weighted according to the number of studies in each comparison.CC BY · PubMed Central
Figure 3 Contribution plot for the coronary artery disease network. The size of each square is proportional to the weight attached to each direct summary effect (horizontal axis) for the estimation of each network summary effects (vertical axis). The numbers re-express the weights as percentages. (MT = medical therapy, PTCA = percutaneous transluminal balloon coronary angioplasty, BMS = bare-metal stents, DES = drug-eluting stents).
Figure 3 Contribution plot for the coronary artery disease network. The size of each square is proportional to the weight attached to each direct summary effect (horizontal axis) for the estimation of each network summary effects (vertical axis). The numbers re-express the weights as percentages. (MT = medical therapy, PTCA = percutaneous transluminal balloon coronary angioplasty, BMS = bare-metal stents, DES = drug-eluting stents).CC BY · PubMed Central
Figure 4 Inconsistency plot for the acute mania network (for the efficacy outcome) assuming loop-specific heterogeneity estimates using the method of moments estimator. (PLA = placebo, ARI = aripiprazole, ASE = asenapine, CARB = carbamazpine, DIV = divalproex, HAL = haloperidol, LAM = lamotrigine, LITH = lithium, OLA = olanzapine, QUE = quetipaine, RIS = risperidone, TOP = topiramate, ZIP = ziprasidone, PAL = paliperidone).
Figure 4 Inconsistency plot for the acute mania network (for the efficacy outcome) assuming loop-specific heterogeneity estimates using the method of moments estimator. (PLA = placebo, ARI = aripiprazole, ASE = asenapine, CARB = carbamazpine, DIV = divalproex, HAL = haloperidol, LAM = lamotrigine, LITH = lithium, OLA = olanzapine, QUE = quetipaine, RIS = risperidone, TOP = topiramate, ZIP = ziprasidone, PAL = paliperidone).CC BY · PubMed Central
Figure 5 Comparison-adjusted funnel plot for the rheumatoid arthritis network. The red line represents the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. The green line is the regression line. Different colours correspond to different comparisons.
Figure 5 Comparison-adjusted funnel plot for the rheumatoid arthritis network. The red line represents the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. The green line is the regression line. Different colours correspond to different comparisons.CC BY · PubMed Central
Figure 6 Predictive interval plot for the rheumatoid arthritis network on a logarithmic scale. The black solid lines represent the confidence intervals for summary odds ratios for each comparison and the red dashed lines the respective predictive intervals. The blue line is the line of no effect (odds ratio equal to 1).
Figure 6 Predictive interval plot for the rheumatoid arthritis network on a logarithmic scale. The black solid lines represent the confidence intervals for summary odds ratios for each comparison and the red dashed lines the respective predictive intervals. The blue line is the line of no effect (odds ratio equal to 1).CC BY · PubMed Central
Figure 7 Plots of the surface under the cumulative ranking curves for all treatments in the rheumatoid arthritis network. Black solid lines correspond to the unadjusted model and red dashed lines to the adjusted for small-study effects model.
Figure 7 Plots of the surface under the cumulative ranking curves for all treatments in the rheumatoid arthritis network. Black solid lines correspond to the unadjusted model and red dashed lines to the adjusted for small-study effects model.CC BY · PubMed Central
Figure 8 Ranking plots for the rheumatoid arthritis network. Treatments have been ranked (a) according to the surface under the cumulative ranking curves (SUCRA) and (b) according to the unique dimension estimated from multidimensional scaling (MDS) approach. Red points correspond to treatments ranked in different order by the two approaches. (PLA = placebo, ABA = abatacept, ADA = adalimumab, ANA = anakinra, ETA = etanercept, INF = infliximab, RIT = rituximab).
Figure 8 Ranking plots for the rheumatoid arthritis network. Treatments have been ranked (a) according to the surface under the cumulative ranking curves (SUCRA) and (b) according to the unique dimension estimated from multidimensional scaling (MDS) approach. Red points correspond to treatments ranked in different order by the two approaches. (PLA = placebo, ABA = abatacept, ADA = adalimumab, ANA = anakinra, ETA = etanercept, INF = infliximab, RIT = rituximab).CC BY · PubMed Central
Figure 9 Clustered ranking plot of the acute mania network based on cluster analysis of SUCRA values for two different outcomes: efficacy and acceptability. Each colour represents a group of treatments that belong to the same cluster. Treatments lying in the upper right corner are more effective and acceptable than the other treatments.
Figure 9 Clustered ranking plot of the acute mania network based on cluster analysis of SUCRA values for two different outcomes: efficacy and acceptability. Each colour represents a group of treatments that belong to the same cluster. Treatments lying in the upper right corner are more effective and acceptable than the other treatments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

Items 201–300 of 1,012

Metadata

Authors
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G.
Affiliations
  • University of Ioannina (GR)
  • University of Bristol (GB)
Corresponding author
Salanti, Georgia
Venue
PLoS ONE
Published
2013-10-03
Volume
8
Issue
10
Pages
e76654
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2091808438
Cited by
2,473
References
51
Citations by year
2026: 222 · 2025: 237 · 2024: 256 · 2023: 252 · 2022: 267 · 2021: 298 · 2020: 228 · 2019: 186 · 2018: 182 · 2017: 154 · 2016: 99 · 2015: 65 · 2014: 26 · 2013: 1
FWCI
70.14
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Bristol Research (University of Bristol) (submittedVersion)
Funders
FP7 Ideas: European Research Council (260559)
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Social Sciences › Sociology and Political Science › Delphi Technique in Research
Keywords
network meta-analysis, graphical tools, treatment ranking, non-statisticians
MeSH terms
Acute Disease, Arthritis, Rheumatoid, Bipolar Disorder, Data Interpretation, Statistical, Humans, Research Design, Meta-Analysis as Topic, Models, Statistical, Odds Ratio, Treatment Outcome, Antirheumatic Agents, Antimanic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.